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INTRODUCTION 
 
 
 
   
Life emerged from oceans more than 3500 milion years ago. Over years of evolution, marine organisms have developed complex biological and chemical 
mechanisms to survive, mainly with the biosynthesis of potent chemical weapons. The pharmaceutical industries recognized this opportunity as new potential ways 
to obtain drugs. Recent progress has resulted in compounds that are being used to treat so important pathologies as cancer or inmunosuppressive disorders. 
Firstly, the main source to obtain active compounds to treat our pathologies was the soil (specifically, from the bacteria and plants), but it is very relevant that 
whereas only 1 over 10.000 earth species is useful to develop new drugs, 1 over 70 marine species is adequate to develop them. It is not surprising so, that in the 
last twenty years, the sea had become the main bioactive molecules source.  
 
OBJECTIVE: The main purpose of the present job is to intensify the awareness of preserving the oceans, presenting a very promising application of marine 
biology: the discovery of new marine drugs against the major human pathologies on the eve of the 21st century.  
 
 
Trabectedin (Yondelis®) 
Conus magus 
Ecteinascidia turbinata 
Ziconotide (Prialt®) 
MARINE DRUGS AS A BOOMING SECTOR 
Tethya crypta 
Vidarabine (Vira-A®) 
Cytarabine (Cytosar-U®) 
“Marine Drugs” is an open-access journal 
publishing on the research, development and 
production of therapeutic agents from marine 
natural products. In recent years it has been 
observed a sudden increase in its number of 
citations and its impact factor (currently it has 
a value of 3,978).  
 
 Commercializing a new marine drug involves a high investment of time and money but provides more profits.  
 Marine drugs are a booming sector. Due to the long time that involves to develop a new drug, the most of marine drugs are sti ll in clinical phases and we will 
have to wait to see the final results. Marine drugs that are currently in use are reporting efficient results for the treatment of many different pathologies, so it is 
expected to happen the same with the new ones.   
 Despite being a relatively new science, marine drugs topic is becoming more and more popular and it is expected to increase i ts popularity for the new years.  
 There are a lot of promising new marine drugs in experimental phases towards the main diseases affecting population of the 21st century and more of them 
expecting to be discovered. Thus, it makes sense to intensify the awareness programs for taking care of the oceans, because we could be contaminating the main 
source of drugs against our future pathologies. 
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HIGHLIGHTS 
TRABECTEDIN: A UNIQUE MECHANISM OF ACTION TOWARDS METASTATIC SOFT TISSUE SARCOMA 
ZICONOTIDE: AN ANALGESIC 1000 TIMES MORE POTENT THAN MORPHINE! 
VIDARABINE AND CYTARABINE: A TURNING POINT IN THE STORY OF AIDS 
 23-79 dC: First quotes about the topic on Pliny the Elder’s book “Naturalis Historia”. Pliny presented the use 
of the sea-wormwood Seriphum against gastrointestinal disturbances. 
 1900: First marine product sensu stricto is commercialized: kainic acid. Obtained from a seaweed, kainic 
acid is a potent central nervous system excitant used in epilepsy research. 
 The gorgonian Plexaura homomalia contains the highest concentrations of prostaglandins in nature. 
 Cephalosporin C was isolated from a marine-derived fungus. It is used as antibiotic and let to synthesize 
analogs that had became some of the first marketed cephalosporin antibiotic drugs. 
 Aequorin is a photoprotein osolated from the hydrozoan Aequorea victoria that lets to follow protein 
pathways allong different organisms.  
 Iota-Carrageenan is the only broad band antiviral therapeutic option available for the treatment of 
respiratory infections. It is obtained by a seaweed.  
 GTS21, designed basing upon a toxin of a nemertin worm (anabasein) is being investigated for the 
treatment of Alzheimer’s disease, nicotine dependence and for schizophrenia. 
 Bryostatins are a group of macrolide lactones isolated from bryozoans. To date 20 different bryostatins have 
been isolated. These promising molecules are currently under investigation as anti-cancer agents and as a 
memory enhancing agent.  
 RefirMARTM: Daily skincare cream. Inhibits the release of acetylcholine at the synapse of the motor neuron. 
In contrast to the well known botulinum toxin (BOTOX®), RefirMARTM does not have a permanent action and 
shows dermal penetrating capacity, avoiding the inconvenience of administration by injection. 
 2004: The First International Symposium on Marine drugs was celebrated in Qingdao. 
 There are mainly three obstacles on developing a new marine drug: budget (it involves around 500 million 
Euros), time (it requires 10 years from the discovery to the aproval of a new drug) and synthetic production on 
a large scale (for example, 1000 kg of bryozoans are needed to obtain 1 g of bryostatin, which is naturally 
unstaintable).  
 Present: A high number of marine drugs are in full development. For example, recently, researchers have 
discovered cnidarins; proteins obtained from corals, capable of blocking the HIV virus from penetrating T-cells. 
Trabectedin, which is also known as ET-743 is an alkaloid isolated from the Caribean ascidian Ecteinascidia 
turbinata. It received firstly marketing authorisation for the treatment of advanced metastatic soft tissue sarcoma, 
and two years later for the treatment of relapsed platinum-sensitive ovarian cancer in combination of other drugs. 
 
Relevance: It was the first antitumoral marine drug to be approved. Currently, is the only way to treat advanced or 
metastatic soft tissue sarcoma. Trabectedin also presents a unique mechanism of action binding to the minor groove 
of the DNA and interfering with cell division and the gene transcription processes and repair machinery of the DNA. 
Ziconotide, which is also known as SNX-111, is a powerful non.opioid analgesic drug approved for the treatment of 
severe chronic pain. It is a synthetic version of ω-conotoxin MVIIA, which is a peptide that is found in the venom of 
the fish-hunting marine snail Conus magus. 
 
Relevance: Ziconotide is 1000 times more potent than morphine. Unlike opiates, prolongate administration of 
ziconotide does not lead to the development of addiction nor tolerance.  
Vidarabine is an antiviral drug that inhibits DNA polymerase and DNA synthesis of herpes, vaccinica and varicella 
zoster viruses. 
 
Cytarabine is a chemotherapy agent that kills cancer cells by interfering with DNA synthesis. It is mainly used for 
the treatment of cancers of white blood cells. 
 
Relevance: Vidarabine and Cytarabine, commonly known respectively as Ara-A and Ara-C, inspired zidovudine 
synthesis, which was the first breakthrough in AIDS therapy. 
RESULTS 
CONCLUSIONS 
REFERENCES 
